HIV molecular immunology database

 

Search Antibody Database

Found 1 matching record:

Displaying record number 681

Download this epitope record as JSON.

MAb ID AD3
HXB2 Location Env Env Epitope Map
Author Location gp120(1-193 BH10)
Epitope (Discontinuous epitope)
Ab Type N-term
Neutralizing  
Species (Isotype) mouse(IgG1)
Patient  
Immunogen vaccine
Keywords antibody generation

Vaccine Details

Vaccine type protein
Vaccine component gp160

Notes

Showing 3 of 3 notes.

References

Showing 3 of 3 references.

Isolation Paper
Dickey2000 C. Dickey, U. Ziegner, M. G. Agadjanyan, V. Srikantan, Y. Refaeli, A. Prabhu, A. Sato, W. V. Williams, D. B. Weiner, and K. E. Ugen. Murine Monoclonal Antibodies Biologically Active against the Amino Region of HIV-1 gp120: Isolation and Characterization. DNA Cell Biol., 19:243-252, 2000. PubMed ID: 10798448. Show all entries for this paper.

Ugen1993 K. E. Ugen, Y. Refaleli, U. Ziegner, M. Agadjanyan, M. A. R. Satre, V. Srikantan, B. Wang, A. Sato, W. V. Williams, and D. B. Weiner. Generation of monoclonal antibodies against the amino terminus of gp120 that elicit antibody-dependent cellular cytotoxicity. Vaccines 93, :215-221, 1993. Editors: F. Brown, H. S. Ginsberg and R. Lerner, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Show all entries for this paper.

Cook1994 D. G. Cook, J. Fantini, S. L. Spitalnik, and F. Gonzalez-Scarano. Binding of Human Immunodeficiency Virus Type 1 HIV-1 gp120 to Galactosylceramide (GalCer): Relationship to the V3 Loop. Virol., 201:206-214, 1994. Antibodies against GalCer can block infection of CD4-negative cells from the brain and colon that are susceptible to HIV infection. This paper explores the ability of a panel of MAbs to inhibit binding of gp120 to GalCer, and also of the binding of GalCer to inhibit MAb-gp120 interaction. MAbs to the V3 loop and GalCer showed mutual inhibition of binding to gp120, and anti-CD4 binding site MAbs showed reduced inhibition. N- and C-terminal MAbs didn't influence GalCer binding. PubMed ID: 8184533. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health